San Francisco, CA, United States of America

Francesco Parlati

This inventor holds 21 USPTO granted patents and 8 published patent applications, plus 4 CIPO patents and 9 EPO patents, primarily in Cancer Treatment. Top assignees: Onyx Therapeutics, Inc., Calithera Biosciences, Inc., Cleave Biosciences, Inc.. Active years: 2010-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Francesco Parlati. Retrieved from https://idiyas.com/inventor/francesco-parlati

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 21 (Patent Applications = 8)

% Patents Active = 61.9

CIPO Patents = 4 (Patent Applications = 6)

EPO Patents = 9 (Patent Applications = 14)

Average Co-Inventor Count = 4.4

ph-index = 7

Forward Citations = 205(Granted Patents)

Location History:

San Francesco, CA (US) (2013)
San Francisco, CA (US) (2010 - 2022)

Company Filing History:

11 out of 50

Onyx Therapeutics, Inc.

patents

6 out of 30

Calithera Biosciences, Inc.

patents

3 out of 7

Cleave Biosciences, Inc.

Years Active: 2010-2022

Loading Chart...

Areas of Expertise:

Arginase Inhibitors

Glutaminase Inhibitors

Immuno-Oncology

Lung Cancer

Enzyme Inhibition

Fused Pyrimidines

P97 Complex

Immunoproteasome

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11291674 - Arginase inhibitor combination therapies (2022-04-05),

2. 10940148 - Combination therapy with glutaminase inhibitors and immuno-oncology agents (2021-03-09),

3. 10441587 - Treatment of lung cancer with inhibitors of glutaminase (2019-10-15),

4. 10278968 - Combination therapy with glutaminase inhibitors (2019-05-07),

5. 10258619 - Combination therapy with glutaminase inhibitors and immuno-oncology agents (2019-04-16),

6. 10010554 - Fused pyrimidines as inhibitors of P97 complex (2018-07-03),

7. 9687485 - Combination therapy with glutaminase inhibitors (2017-06-27),

8. 9657058 - Compounds for enzyme inhibition (2017-05-23),

9. 9475824 - Fused pyrimidines as inhibitors of p97 complex (2016-10-25),

10. 9359398 - Compounds for immunoproteasome inhibition (2016-06-07),

11. 9062026 - Fused pyrimidines and substituted quinazolines as inhibitors of p97 (2015-06-23),

12. 8765745 - Compounds for enzyme inhibition (2014-07-01),

13. 8735441 - Compounds for enzyme inhibition (2014-05-27),

14. 8697837 - Substrate for Rpn 11 enzymatic activity (2014-04-15),

15. 8609654 - Compounds for enzyme inhibition (2013-12-17),

Title: The Innovative Journey of Francesco Parlati

Introduction: Francesco Parlati, a visionary inventor based in San Francisco, CA, has made significant contributions to the world of technology and innovation through his groundbreaking inventions.

Latest Patents: Francesco Parlati holds several patents in the field of artificial intelligence and renewable energy technologies, showcasing his commitment to creating a sustainable future.

Career Highlights: With a background in engineering and a passion for problem-solving, Francesco Parlati has led numerous successful projects that have revolutionized industries such as clean energy, healthcare, and transportation.

Collaborations: Throughout his career, Francesco Parlati has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work across disciplines has led to the development of cutting-edge solutions that have had a lasting impact.

Conclusion: Francesco Parlati's innovative spirit and dedication to pushing the boundaries of technology have solidified his reputation as a pioneering inventor in the vibrant city of San Francisco, CA.

Profile summary based on public USPTO records.